Intellectual Property
Apr. 6, 2011
Ginger R. Dreger
Portfolio Manager / Patent Prosecutor Arnold & Porter LLP San Francisco Biotechnology
Arnold & Porter LLP
San Francisco
Biotechnology
While coordinating intellectual property strategy for biotechnology companies involved in therapeutics, personalized medicine and diagnostics, Dreger is waiting for clarification from the courts on whether genes and certain diagnostic methods can be patented.
The stakes are high for companies that use genetic information to develop treatments...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In